[Long-term safety of using tiagabine in epilepsy].
Tiagabine (TGB) is a novel antiepileptic drug efficacious for the treatment of partial epilepsies. The aim of that work is short presentation of current data concerning long-term safety of TGB. Tolerance to TGB does not develop with long-term therapy. Idiosyncratic reaction and changes in haematology and chemistry values have not been associated with TGB therapy. The most common adverse effects are dizziness, asthenia, nervousness, tremor, diarrhoea and depression. The current data do not show any evidence of relationship between visual field constriction and TGB treatment. No adverse effects on cognitive abilities have been found. There are contradictory data concerning tiagabine-induced nonconvulsive status epilepticus. Because of high safety and efficacy TBG is an important new antiepileptic drug for the treatment of intractable partial epilepsies.
Oddział Neurologii Dzieciecej Szpitala im. T. Marciniaka we Wrocławiu.
A
A
Kozik
D000818:Animals; D000927:Anticonvulsants; D004361:Drug Tolerance; D004569:Electroencephalography; D004828:Epilepsies, Partial / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D009557:Nipecotic Acids / Q000009:adverse effects*; D011605:Psychoses, Substance-Induced / Q000209:etiology; D000078308:Tiagabine; D014786:Vision Disorders / Q000139:chemically induced
D000927:Anticonvulsants; D009557:Nipecotic Acids; D000078308:Tiagabine